Table 6 Observed cancer cases for the MLH1 cohort with 100% or 50% probability of MMR mutation (excluding colorectal and endometrial cancer)
From: A retrospective study of extracolonic, non-endometrial cancer in Swedish Lynch syndrome families
Primary site | Observed number | Proportion [%] | LL 95% | UL 95% | Proportion [%] in Sweden 1970 | Proportion [%] in Sweden 2010 | Reference outside CI |
|---|---|---|---|---|---|---|---|
Breast | 28 | 17.72 | 12.03 | 24.05 | 16.61 | 23.02 | No |
Stomach | 26 | 16.46 | 10.76 | 22.15 | 6.31 | 1.4 | above |
Kidney/urinary tract excl prostate | 16 | 10.13 | 5.7 | 15.19 | 8.99 | 5.77 | No |
Skin excl melanoma | 12 | 7.59 | 3.8 | 12.03 | 1.76 | 4.5 | No |
Pancreas | 11 | 6.96 | 3.16 | 11.39 | 2.66 | 1.6 | above |
Brain and nervous system | 10 | 6.33 | 2.53 | 10.13 | 6.61 | 5.34 | No |
Ovary and Fallopian tube | 8 | 5.06 | 1.9 | 8.86 | 4.97 | 2.02 | No |
Small bowel | 7 | 4.43 | 1.27 | 7.59 | 0.57 | 0.57 | above |
Liver and biliary system | 6 | 3.8 | 1.27 | 6.96 | 2.52 | 1.65 | No |
Malignant melanoma | 6 | 3.8 | 1.27 | 6.96 | 4.98 | 10.18 | No |
Cervix | 5 | 3.16 | 0.63 | 6.33 | 5.79 | 2.08 | No |
Prostate | 5 | 3.16 | 0.63 | 6.33 | 4.26 | 11.02 | No |
Head and neck | 4 | 2.53 | 0.63 | 5.06 | 3.69 | 2.95 | No |
Lung and airways | 4 | 2.53 | 0.63 | 5.06 | 6.79 | 5.46 | below |
Oesophagus | 3 | 1.9 | 0 | 4.43 | 0.74 | 0.58 | No |
Blood and lymphatic tissue | 3 | 1.9 | 0 | 4.43 | 10.02 | 9.72 | below |
Bone and soft tissue | 2 | 1.27 | 0 | 3.16 | 1.75 | 1.17 | No |
Testicle | 1 | 0.63 | 0 | 1.9 | 1.98 | 3.65 | below |
Thyroid | 1 | 0.63 | 0 | 1.9 | 1.68 | 2.22 | No |
Female genital organ | 0 | 0 | 0 | 0 | 0.54 | 0.33 | below |
Penis | 0 | 0 | 0 | 0 | 0.32 | 0.18 | below |
Eye | 0 | 0 | 0 | 0 | 0.48 | 0.35 | below |
Endocrine cancer | 0 | 0 | 0 | 0 | 2.66 | 2.12 | below |
Unspecified location | 0 | 0 | 0 | 0 | 3.32 | 2.14 | below |